Deprescribing anticholinergic and sedative drugs to reduce polypharmacy in frail older adults living in the community: a randomized controlled trial.
Hamish JamiesonPrasad S NishtalaHans Ulrich BerglerSusan K WeaverJohn W PickeringNagham J AilabouniRebecca Abey-NesbitCarolyn GulleryJoanne DeelySusan B GeeSarah Nicole HilmerDee ManginPublished in: The journals of gerontology. Series A, Biological sciences and medical sciences (2023)
Our pharmacist-led medication review of frail older participants did not reduce the anticholinergic/sedative load within six months. Covid-19 lockdown measures required modification of the intervention. Subgroup analyses pre- and post-lockdown showed no impact on outcomes. Reviewing this and other deprescribing trials through the lens of implementation science may aid an understanding of the contextual determinants preventing or enabling successful deprescribing implementation strategies.
Keyphrases
- healthcare
- community dwelling
- primary care
- physical activity
- coronavirus disease
- sars cov
- quality improvement
- randomized controlled trial
- public health
- mental health
- adverse drug
- emergency department
- middle aged
- type diabetes
- clinical trial
- respiratory syndrome coronavirus
- drug induced
- adipose tissue
- study protocol
- phase iii
- open label
- weight loss